Quantum BioPharma Ltd. Asset Resilience Ratio
Quantum BioPharma Ltd. asset resilience ratio. Quantum BioPharma Ltd. (QNTM) has an Asset Resilience Ratio of 42.37% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See QNTM cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Quantum BioPharma Ltd. (2020–2025)
Asset resilience ratio of Quantum BioPharma Ltd. from 2020 to 2025. This chart shows how Quantum BioPharma Ltd.'s Asset Resilience Ratio has changed over time. Read how much debt does Quantum BioPharma Ltd. carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Quantum BioPharma Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Quantum BioPharma Ltd. asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.09 Million | 42.37% |
| Total Liquid Assets | $6.09 Million | 42.37% |
Asset Resilience Insights
- Very High Liquidity: Quantum BioPharma Ltd. maintains exceptional liquid asset reserves at 42.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Quantum BioPharma Ltd. Industry Peers by Asset Resilience Ratio
Compare Quantum BioPharma Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Genmab A/S
CO:GMAB |
Biotechnology | 23.50% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Viking Therapeutics Inc
NASDAQ:VKTX |
Biotechnology | 72.03% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
Quantum BioPharma Ltd. Asset Resilience Ratio by Year (2020–2025)
Quantum BioPharma Ltd. asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Quantum BioPharma Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 38.30% | $4.27 Million | $11.14 Million | +31.28pp |
| 2024-12-31 | 7.02% | $1.20 Million | $17.12 Million | +2.70pp |
| 2023-12-31 | 4.33% | $756.10K | $17.47 Million | +4.27pp |
| 2022-12-31 | 0.06% | $23.19K | $38.41 Million | -0.19pp |
| 2021-12-31 | 0.25% | $158.04K | $62.96 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $41.97 Million | -- |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more